Image via Yahoo Finance
Gilead Sciences: Ma Activity
Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Source: Yahoo Finance
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
Market context: The wider read — a Talent Market Index of 98.6 (Neutral), down 1.4 month-on-month — shows Americas signal flow easing (-2.6pts).
Gilead Sciences: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 19 tracked companies; 0.3% of MitchelLake's Asia signal flow; 3 tracked across 62 days.
MitchelLake in this thematic
Also at Gilead Sciences →
More signals across Biotech & Pharma
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Partnership · Americas
Ratio Therapeutics →Ratio Therapeutics expanded manufacturing collaboration with PharmaLogic to add capacity and redundancy for clinical development of lead radiotherapeutic candidate BOSTON
Intelligence powered by Autonodal ↗